We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Immunoblot Test Differentiates Pollen Allergies Diagnoses

By LabMedica International staff writers
Posted on 28 Jun 2018
Specific immunoglobulin E (IgE) antibodies against inhalation allergens that commonly occur in Southern Europe can be detected and differentiated using a new multiparameter immunoblot test.

The test is based on defined partial allergens (DPA, allergen components) and the detailed profile identifies the precise allergy-causing proteins, distinguishing primary sensitizations from cross-reactions and thus aiding therapy decision-making.

The test is based on a unique combination of species-specific marker molecules, cross-reactive components and whole extracts, encompassing tree pollens (birch, olive, cypress, hazel, oak), grass pollens (timothy grass, wall pellitory) and the fungus Alternaria alternata. More...
The native extracts provide a general screening for IgE antibodies against the respective pollen/fungus.

The multiparameter immunoblot EUROLINE DPA-Dx Pollen Southern Europe 1 test (EUROIMMUN AG, 23560 Luebeck, Germany) is a combination of the Southern European species-specific marker molecules together with common panallergens, such as PR-10 proteins and profilin, enables precise discrimination between a putative primary sensitization and a persistent cross reaction. Positive reactions with species-specific markers are an indication for specific immunotherapy. Positive reactions with panallergens on the other hand indicate cross-reactions. Cross-reactive molecules are prevalent among different types of plants, which often results in a high sensitization rate. An insufficient differentiation between primary sensitization and cross-reactions often results in a less effective desensitization during specific immunotherapy.

The test also includes a band of cross reactive carbohydrate determinants (CCD), which aids the differentiation of clinically relevant reactions from unspecific anti-CCD reactions and thus the interpretation of results. With this in-depth profile, true sensitizations can be reliably identified, enabling targeted selection of the most suitable specific immunotherapy and improved prognosis of the therapy success. The test is easy to perform and requires only a small sample volume. The high analytical and clinical value of the profile has been verified in an independent study. Automated processing and evaluation are available for the assay.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.